読み込み中
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
通常取引
$0.955
−$0.0036 · -0.38%
日中の時刻はETです。市場データは遅延する場合があります。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日中レンジ
現在 $0.955
52週レンジ
現在 $0.955
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
36
割高
センチメント
47
まちまち
リスク
70
高リスク
モメンタム
39
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日中レンジ
現在 $0.955
52週レンジ
現在 $0.955
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 2566.29万 USD | 4822.48万 USD | 2945.87万 USD | 4730.61万 USD | 4493.65万 USD |
| 販売・一般管理 | 960.24万 USD | 1189.22万 USD | 1333.54万 USD | 1537.39万 USD | 1128.3万 USD |
| 営業費用 | 3526.52万 USD | 6011.7万 USD | 4279.41万 USD | 6268万 USD | 5621.95万 USD |
| 受取利息 | 332.39万 USD | 619.18万 USD | 732.3万 USD | 234.94万 USD | 18.54万 USD |
| 支払利息 | 190.53万 USD | 192.62万 USD | 207.1万 USD | 169.41万 USD | 174.21万 USD |
| 減価償却費と償却費 | 25.2万 USD | 24.96万 USD | 26.28万 USD | 25.87万 USD | 26.42万 USD |
| 営業利益 | −3526.52万 USD | −6011.7万 USD | −4279.41万 USD | −6268万 USD | −5621.95万 USD |
| 純利益 | −3384.67万 USD | −5585.14万 USD | −3754.25万 USD | −6202.46万 USD | −5777.63万 USD |
会社概要が更新されました 2026年10月8日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI264.1万0.00%2.3兆 USD0.03%$379.42-0.42%
Vanguard Extended Market ETFVXF84.9万0.00%954億 USD0.05%$233.16-0.14%
Vanguard Health Care ETFVHT24.79万0.00%220億 USD0.09%$313.61-0.54%
iShares Micro-Cap ETFIWC17.97万0.01%13.33億 USD0.60%$182.53-0.46%
Invesco RAFI US 1500 Small-Mid ETFPRFZ9.87万0.00%26.84億 USD0.36%$52.795+0.12%
Invesco NASDAQ Future Gen 200 ETFQQQS7.76万0.34%2296.09万 USD0.20%$41.4482-1.37%
Dimensional - US Small Cap ETFDFAS3.82万0.00%336.6億 USD0.31%$78.165+0.31%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
